Dietary immunosuppressants do not enhance UV-induced skin carcinogenesis, and reveal discordance between p53-mutant early clones and carcinomas

Cancer Prevention Research

Volumn 6, Issue 2, 2013, Pages 129-138

  Voskamp, Pieter ^a   Bodmann, Carolien A ^a   Koehl, Gudrun E ^b   Rebel, Heggert G ^a   Van Olderen, Marjolein G E ^a   Gaumann, Andreas ^c   El Ghalbzouri, Abdoel ^a   Tensen, Cornelis P ^a   Bavinck, Jan N Bouwes ^a   Willemze, Rein ^a   Geissler, Edward K ^b   De Gruijl, Frank R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CASPASE 3; CYCLOSPORIN; MERCAPTOPURINE; MYCOPHENOLIC ACID; PROTEIN P53; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RISK; CELL COUNT; CELL PROLIFERATION; CODON; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN CARCINOMA; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CLONE CELLS; DIET; DISEASE PROGRESSION; FEMALE; GENES, P53; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, HAIRLESS; MUTANT PROTEINS; MUTATION; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 84874497821     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0361     Document Type: Article

References (48)

1. Hartevelt MM, Bavinck JNB, Kootte AMM, Vermeer BJ, Vandenbroucke JP. Incidence of skin-cancer after renal-transplantation in the Netherlands. Transplantation 1990;49:506-9.
2. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996;61:715-21.
3. Bavinck JN, De Boer A, Vermeer BJ, HarteveltMM, van der Woude FJ, Claas FH, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
5. Kripke ML, Fisher MS. Immunologic aspects of tumor induction by ultraviolet radiation. Natl Cancer Inst Monogr 1978:179-83.
6. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125:1020-5.
7. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987;44:429-34.
8. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu Y-Z, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4.
9. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000;47:63-83
10. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009;2:pe24.
11. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010;468:1100-4.
12. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008;8:2212-8.
13. Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987;117:429-40.
14. Reeve VE, Greenoak GE, Gallagher CH, Canfield PJ, Wilkinson FJ. Effect of immunosuppressive agents and sunscreens on UV carcinogenesis in the hairless mouse. Aust J Exp Biol Med Sci 1985;63 (Pt 6):655-65.
15. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994;57:568-73.
16. Engl T, Makarevic J, Relja B, Natsheh I, Muller I, Beecken WD, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005;5:4.
17. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
18. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004;77:1319-26.
19. Koehl GE, Gaumann A, Zuelke C, Hoehn A, Hofstaedter F, Schlitt HJ, et al. Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 2006;82:741-8.
20. de Graaf YG, Rebel H, Elghalbzouri A, Cramers P, Nellen RG, Willemze R, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008;17:349-55.
21. Voskamp P, Bodmann CA, Rebel HG, Koehl GE, Tensen CP, Bouwes Bavinck JN, et al. Rapamycin impairs UV induction of mutant-p53 overexpressing cell clusters without affecting tumor onset. Int J Cancer 2012;131:1267-76.
22. Salgo R, Gossmann J, Schöfer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessorblinded, controlled clinical trial. Am J Transplantation 2010;10:1385-93.
23. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39.
24. El-Ghalbzouri A, Gibbs S, Lamme E, Van Blitterswijk CA, Ponec M. Effect of fibroblasts on epidermal regeneration. Br J Dermatol 2002;147:230-43.
25. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007;49:201-8.
26. Odlind B, Hartvig P, LindströmB, Lönnerholm G, Tufveson G, Grefberg N. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. Intl J Immunopharmacol 1986;8:1-11.
27. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
28. de Gruijl FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2010;127:796-804.
29. Rebel H, Kram N, Westerman A, Banus S, van Kranen HJ, de Gruijl FR. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. Carcinogenesis 2005;26:2123-30.
30. Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci 2012; 11:62-8.
31. Takeuchi S, Zhang W, Wakamatsu K, Ito S, Hearing VJ, Kraemer KH, et al. Melanin acts as a potentUVBphotosensitizer to cause an atypical mode of cell death in murine skin. Proc Natl Acad Sci U S A 2004; 101:15076-81.
32. Sugie N, Fujii N, Danno K. Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 2002;18:163-8.
33. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1555-61.
34. Flockhart RJ, Diffey BL, Farr PM, Lloyd J, Reynolds NJ. NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. FASEB J 2008;22:4218-27.
35. Kramata P, Lu Y-P, Lou Y-R, Singh RN, Kwon SM, Conney AH. Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. Cancer Res 2005;65:3577-85.
36. Stahl PL, Stranneheim H, Asplund A, Berglund L, Ponten F, Lundeberg J. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol 2011;131:504-8.
37. King P, Craft AW, Malcolm AJ. p53 Expression in three separate tumours from a patient with Li-Fraumeni's syndrome. J Clin Pathol 1993;46:676-7.
38. Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008;128:2467-73.
39. Duncan FJ, Wulff BC, Tober KL, Ferketich AK, Martin J, Thomas-Ahner JM, et al. Clinically relevant immunosuppressants influence UVBinduced tumor size through effects on inflammation and angiogenesis. Am J Transplantation 2007;7:2693-703.
40. Therapeutic Drug Monitoring of Tacrolimus. Dutch Society of Hospital Pharmacist; 2005. Available from: http://www.2nvza.nl/uploaddb/ downl-object.asp?atoom=5858&VolgNr=1
41. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010;10:94-101.
42. Lash AA. Anticancer drugs for noncancer diseases. Medsurg Nurs 1996;5:177,180-4,190.
43. Brem R, Karran P. Oxidation-mediated DNA cross-linking contributes to the toxicity of 6-thioguanine in human cells. Cancer Res 2012;72:4787-95.
44. Rebel H, Mosnier LO, Berg RJW, Westerman-de Vries A, van Steeg H, van Kranen HJ, et al. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity. Cancer Res 2001;61:977-83.
45. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996;93:14025-9.
46. Berg RJ, van Kranen HJ, Rebel HG, de Vries A, van Vloten WA, Van Kreijl CF, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci 1996;93:274-8.
47. le Pelletier F, Soufir N, de La Salmoniere P, Janin A, Basset-Seguin N. p53 Patches are not increased in patients with multiple nonmelanoma skin cancers. J Invest Dermatol 2001;117:1324-5.
48. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-67.